Elevation Oncology to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

Rhea-AI Summary

Elevation Oncology, Inc. (Nasdaq: ELEV) announced participation by CEO Shawn M. Leland in a pre-recorded fireside chat at the H.C. Wainwright BIOCONNECT Virtual Conference on January 10, 2022. The company focuses on precision medicines for patients with genomically defined cancers, with its lead candidate, seribantumab, targeting NRG1 fusions in solid tumors. The presentation will be available on-demand from 7:00 a.m. ET on the company's investor relations website.

NEW YORK, Jan. 6, 2022 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, today announced that Shawn M. Leland, PharmD, RPh, Elevation Oncology's Founder and Chief Executive Officer, will participate in a pre-recorded fireside chat at the H.C. Wainwright BIOCONNECT Virtual Conference.

An on-demand replay of the presentation can be accessed beginning Monday, January 10, 2022, at 7:00 a.m. ET on the Events page of the Company's Investor Relations website at https://investors.elevationoncology.com.

About Elevation Oncology, Inc.
Elevation Oncology is founded on the belief that every patient living with cancer deserves to know what is driving the growth of their disease and have access to therapeutics that can stop it. We aim to make genomic tests actionable by selectively developing drugs to inhibit the specific alterations that have been identified as drivers of tumor growth. Together with our peers, we work towards a future in which each tumor's unique genomic test result can be matched with a purpose-built precision medicine to enable an individualized treatment plan for each patient. Our lead candidate, seribantumab, is intended to inhibit tumor growth driven by NRG1 fusions and is currently being evaluated in the Phase 2 CRESTONE study for patients with solid tumors of any origin that have an NRG1 gene fusion. Details on CRESTONE are available at www.NRG1fusion.com. For more information visit www.ElevationOncology.com.

Elevation Oncology Investor and Media Contact
Candice Masse, 978-879-7273
Senior Director, Corporate Communications & Investor Relations
cmasse@elevationoncology.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/elevation-oncology-to-present-at-the-hc-wainwright-bioconnect-virtual-conference-301454472.html

SOURCE Elevation Oncology

FAQ

What is Elevation Oncology's participation in the H.C. Wainwright BIOCONNECT Virtual Conference on January 10, 2022?

Elevation Oncology's CEO, Shawn M. Leland, will participate in a pre-recorded fireside chat at the conference.

What is the lead candidate of Elevation Oncology and what does it target?

Elevation Oncology's lead candidate is seribantumab, which targets NRG1 fusions in solid tumors.

When can I access the on-demand replay of Elevation Oncology's presentation from the conference?

The on-demand replay will be available starting January 10, 2022, at 7:00 a.m. ET.

Where can I find more information about Elevation Oncology's events?

More information can be found on Elevation Oncology's investor relations website.

What is the significance of NRG1 fusions in Elevation Oncology's research?

NRG1 fusions are specific genetic alterations targeted by seribantumab, aimed at inhibiting tumor growth.